Stay updated on Fisogatinib in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe ClinicalTrials.gov page now displays the completed fisogatinib Phase 1 study record, including its eligibility criteria, locations, and study outcomes, instead of a 403 error.SummaryDifference59%

- Check19 days agoChange DetectedThe ClinicalTrials.gov site revision displayed in the footer changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check26 days agoChange DetectedA dismissible notice announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” in response to an executive order.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates that core study information is not accessible on the page.SummaryDifference17%

Stay in the know with updates to Fisogatinib in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fisogatinib in Hepatocellular Carcinoma Clinical Trial page.